0000000000644302

AUTHOR

Elena Rachlis

showing 2 related works from this author

Impact of Donor-Recipient Histocompatibility and CMV-Mismatch on Outcome of Allogeneic Stem Cell Transplantation for AML and MDS: A Retrospective Reg…

2016

Abstract Introduction Allogeneic stem cell transplantation (allo-SCT) is a curative treatment for several hematological diseases. Donor-recipient histo-incompatibility is associated with poorer outcome. Transplant outcome of CMV positive patients is reported to be poorer, if the unrelated donor is CMV negative (CMV-mismatch). Recent developments in transplant strategies including high resolution HLA-typing, toxicity-reduced conditioning regimens, CMV-monitoring, and improved supportive care have made transplants from HLA- as well as CMV- mismatched unrelated donors more feasible. We present a retrospective registry analysis from a large, and recent cohort of patients transplanted under thes…

0301 basic medicinemedicine.medical_specialtyProportional hazards modelbusiness.industryDonor selectionImmunologySubgroup analysisCell BiologyHematologyHuman leukocyte antigenBiochemistrySurgeryHistocompatibilityTransplantation03 medical and health sciences030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesisInternal medicineCohortmedicineAlemtuzumabbusinessmedicine.drugBlood
researchProduct

Relative Impact of HLA Matching and Non-HLA Donor Characteristics on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and …

2018

Increasing donor-recipient HLA disparity is associated with negative outcomes of allogeneic hematopoietic stem cell transplantation (HSCT), but its comparative relevance amid non-HLA donor characteristics is not well established. We addressed this question in 3215 HSCTs performed between 2005 and 2013 in Germany for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Donors were HLA-matched related (MRD; n = 872) or unrelated (10/10 MUD, n = 1553) or HLA-mismatched unrelated (10/10 MMUD, n = 790). Overall survival (OS) was similar after MRD compared with 10/10 MUD HSCT, reflecting opposing hazards of relapse (hazard ratio [HR], 1.32; P.002) and nonrelapse mortality (HR, .63; P.0…

AdultMaleOncologymedicine.medical_specialtymedicine.medical_treatmentMedizinHematopoietic stem cell transplantationHuman leukocyte antigenDonor age03 medical and health sciences0302 clinical medicineRecurrenceInternal medicinemedicineHumansTransplantation HomologousTransplantationbusiness.industryHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyMiddle AgedTissue DonorsTransplantationLeukemia Myeloid AcuteTreatment OutcomeMale patientMyelodysplastic Syndromes030220 oncology & carcinogenesisAllogeneic hsctFemaleStem cellbusiness030215 immunologyBiology of Blood and Marrow Transplantation
researchProduct